SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending due to positive third-quarter financial results, with revenue and EPS exceeding expectations, sparking bullish sentiment. The community is discussing the company's AI integration and potential beyond just gaming, as well as the growth of Unity Vector. Some investors see the recent earnings as a sign of improved execution and an attractive adtech/fintech ecosystem.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending as the community discusses the ongoing bidding war with Pfizer for Metsera, with some questioning the aggressive pursuit given NVO's existing pipeline and others speculating about potential impacts on competition. Community members are also analyzing recent earnings and forward guidance, weighing the potential of upcoming FDA approvals against concerns about management strategy and competition from Eli Lilly.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart ($UPST) is trending amidst discussions around its Q3 earnings and future prospects; while some express concerns about the company's business model and potential risks related to loan performance, others point to positive growth metrics and potential for a short squeeze. Community members are debating whether the recent price action reflects market manipulation or genuine concerns about the company's fundamentals, particularly in light of broader economic uncertainties and the performance of comparable fintech companies. The stock's high short interest and upcoming earnings are fueling speculation about a potential squeeze.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind ($MNKD) is trending due to recent quarterly results showing increased Afrezza sales and royalties, alongside the completed acquisition of scPharmaceuticals. The community is actively discussing the potential impact on future coverage from Morgan Stanley and Goldman Sachs, as well as updates on clinical trials and revenue projections. Some investors are expressing frustration with the stock's movement despite positive news.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as the community rallies around the meme coin, emphasizing its resilience and strong community. Talk centers around the coin's ability to hold strong despite market liquidations, with participants highlighting the coin's real-world partnerships and sponsorships. The community uses the phrase "that slaps" to express excitement and are focused on onboarding new users to crypto through IRL events.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid mixed sentiment following recent Q3 earnings and key strategic updates, including reaffirmed timelines for the R2 launch and the introduction of Mind Robotics. While some community members express bullish views on long-term potential, others remain skeptical about profitability and execution, particularly regarding the R2's success. Discussions also revolve around Rivian's positioning in the EV market relative to competitors like Tesla, as well as potential impacts from partnerships and industry trends.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending amidst analyst optimism and community discussion around its growth strategy, particularly highlighting Needham's updated rating to "Buy". Investors are contrasting ZETA's acquisition approach with other AI players and anticipating an upgrade cycle, while also noting the company's OpenAI partnership. The community is actively debating fundamentals and potential price movements, with some focusing on its ability to quietly add enterprise clients and deliver measurable growth.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending due to community discussion around a potential buyout offer from Nestle following recent financial results and business updates; the lack of confirmation from the company regarding buyout rumors is fueling speculation and frustration, as investors debate the likelihood of a deal versus a partnership or other strategic alternatives. Disappointment from a recent conference call has also added to investor unease, as some feel management danced around key questions about rumors of a buyout offer and future capital needs.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean ($DOCN) is trending as investors react positively to strong earnings, with revenue growth and AI initiatives driving excitement. The community highlights the company's focus on SMBs and its potential as an acquisition target, fueling discussions about its long-term growth prospects. Bullish sentiment is further supported by positive analyst ratings and price target increases.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid political chatter and election outcomes, with community members debating the stock's valuation and its ties to narratives and emotion rather than fundamentals. Some traders are pointing to the stock's volatility, while others are highlighting alternative investments with stronger data or enterprise growth. The broader discussion includes contrasting perspectives on the political climate and potential impacts on the market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure

Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Association (AHA) Scientific Sessions 2025 November...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Companys Board of Directors approved...

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of...

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy

Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.

Arrowhead Pharmaceuticals, Inc. (ARWR) on Tuesday announced a global licensing and collaboration agreement with Swiss pharmaceutical giant Novartis (NVS) for its investigational therapy for the treatment of neurodegenerative disorders such as Parkinson’s Disease.Under the agreement, Novartis will receive an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA, a preclinical-stage program for the potential treatment of patients with Parkinson’s disease and other synucleinopathies. Novartis will also select additional collaboration targets outside of Arrowhead’s current pipeline to be developed using Arrowhead’s Targeted RNAi Molecule (TRiM) platform, Arrowhead said.Meanwhile, Arrowhead will <a target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-and-novartis-enter-into-a-global-license-and-collaboration-agreement/">receive</a> a $200 million upfront payment and is eligible to receive up to $2 billion in potential milestone payments, in addition to royalties on commercial sales.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> rose by 11% at the time of writing, while NVS stock traded marginally in the red. On Stocktwits, retail sentiment around ARWR stayed within ‘bearish’ territory over the past 24 hours, while message volume rose to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_9_57_14_AM_png_dadf30ac72.webp" alt="ARWR's Sentiment Meter and Message Volume as of 9:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>ARWR's Sentiment Meter and Message Volume as of 9:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_10_00_31_AM_png_703e9e6f44.webp" alt="NVS's Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="574" height="60"><figcaption>NVS's Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that Arrowhead getting $200 million upfront for a pre-clinical asset is a “hell of a deal.”<stembedurl>https://stocktwits.com/Pika_Capital/message/627215281</stembedurl>Arrowhead will conduct and complete the necessary preclinical research activities to enable the filing of a clinical trial application for all licensed programs under the agreement. Novartis will then assume sole control over development, manufacturing, medical affairs, and commercialization activities. The transaction is expected to close in the second half of 2025.CEO Christopher Anzalone stated that the company looks forward to beginning clinical trials for ARO-SNCA “as soon as possible.” Both ARWR stock and NVS stock is up by about 30% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-stock-tanks-after-cancer-drug-candidate-update/chv6sI8Rdny">Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

Under the agreement, Arrowhead will receive a $200 million upfront payment and is eligible to receive up to $2 billion in potential milestone payments, as well as royalties on commercial sales.

Equity

H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its credibility in capital allocation.The firm also highlighted concerns that Sarepta's late-stage and commercial portfolio may not generate sufficient near-term cash to support its current debt and pipeline ambitions.H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. The brokerage noted that <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> fully unwound its equity position in Arrowhead less than a year after investing $325 million in the stock. The unwinding represented a 31% decline as compared to the purchase price, it added.On Stocktwits, retail sentiment around the stock trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Retail chatter around the stock jumped 131% over the past 24 hours, as of Thursday morning.<figure class="image"><img style="aspect-ratio:625/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_11_12_15_AM_png_aaca6c7ce4.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="625" height="58"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Sarepta selling its investment in Arrowhead.<stembedurl>https://stocktwits.com/Zergg/message/625149352</stembedurl>Another user hopes the stock will hit $30 by next week.<stembedurl>https://stocktwits.com/markxtill/message/625143002</stembedurl>Sarepta on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-keeps-retail-traders-bullish-as-stock-surges-on-100-m-milestone-payment-to-arrowhead-in-genetic-disorder-trial/chsR9ZARdak">said</a> that it sold about 9.27 million shares of common stock of Arrowhead in a privately negotiated block trade from which it expects to receive at least $174 million in gross proceeds.The company also said that it has entered into an agreement with Arrowhead under which it will transfer over 2.66 million shares of <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> back to the company to satisfy a $50 commitment of a $100 milestone payment obligation. The remaining $50 million will be received in cash, Arrowhead said. Sarepta previously owned 11.93 million shares of Arrowhead stock.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.However, SRPT stock is down by 84% this year and by 85% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hertz-expands-program-allowing-prolonged-3-day-test-drives-before-vehicle-purchase-to-over-100-cities/chsRlcNRdOh">Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review and enrollment progress in its Phase 1/2 trial of SRP-1003 for type 1 myotonic dystrophy (DM1) triggered a $100 million milestone payment to Arrowhead Pharmaceuticals.<a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> jumped 8.5% to close at $20.4 on Wednesday, with an additional 1.6% gain in after-hours trading.The payment was triggered after Arrowhead reached the first of two predetermined enrollment targets in the study, following a review of the safety data.&nbsp;SRP-1003 is an experimental RNA interference therapy being developed for type 1 myotonic dystrophy.To help fund the milestone payment, Sarepta sold 9.3 million shares of Arrowhead in a privately negotiated block trade, generating at least $174 million in gross proceeds.&nbsp;Arrowhead will also redeem 2.7 million shares from Sarepta for $50 million, prefunding half of the milestone obligation.The company plans to share early results from the SRP-1003 trial and its facioscapulohumeral muscular dystrophy (FSHD) program in the second half of 2025.On Stocktwits, retail sentiment was ‘bullish’ for Sarepta Therapeutics and ‘extremely bullish’ for Arrowhead Pharmaceuticals, with 24-hour message volumes surging 872% and 122%, respectively.One user remarked that upgrades for Sarepta Therapeutics keep coming, adding that the market may be underestimating how quickly sentiment can shift when major investors get involved.&nbsp;<stembedurl>https://stocktwits.com/BookerB/message/625098239</stembedurl>Another said the stock could still rise tenfold within a year if European approval comes through and with multiple trials underway, calling it a bargain and urging others to buy before the current discount disappears.<stembedurl>https://stocktwits.com/Mejeko/message/625096804</stembedurl>While Sarepta’s stock has declined 83.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/ARWR">Arrowhead’s stock</a> gained 6.3% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$37.85
Prev Close	$39.61
Open	$38.60
Dividend Yield	0.00%
50-Day Moving Average	$33.32
Beta	1.63
Avg. Volume	1.8M
PE Ratio	-29.96

52-Week High	$43.69
52-Week Low	$9.57
Market Capitalization	$5.23B
EPS (Annual)	-$5.00
Price to Book	10.01
Revenue Per Employee	$5,830.87
Enterprise Value/EBITDA	N/A

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.